Hayward, Calif. — Aqtual appointed Daniil Kalyuzhny as chief financial officer as the precision medicine company advances its liquid biopsy platform and prepares its first therapy-selection test for clinical validation and commercialization.
Kalyuzhny will oversee the company’s financial strategy, capital formation and strategic transactions. He will also support Aqtual’s clinical programs, platform development and expansion of its proprietary biobank.
“The opportunity in front of Aqtual has expanded, and this is the right time to add Daniil’s perspective to the team,” said Diana Abdueva, Ph.D., founder and CEO of Aqtual. “He brings the sector judgment and transaction experience to help us set priorities, make the right calls and execute.”
Kalyuzhny most recently served as a managing director in BTIG’s Global Healthcare Group, where he led investment banking coverage for the diagnostics and life sciences tools sector.
He has more than a decade of experience advising precision medicine, diagnostics and life sciences companies on mergers and acquisitions, financings and strategic partnerships.
During his investment banking career, Kalyuzhny advised management teams on transactions totaling more than $25 billion.
“One of the defining challenges for platform companies is deciding where to invest, where to partner and how to allocate capital across multiple opportunities,” Kalyuzhny said.
“Aqtual has built an exceptional scientific foundation with multiple paths to creating long-term value. I’m excited to join the team and help build the financial strategy that supports the company’s long-term vision,” he added.
Aqtual is developing active chromatin cell-free DNA diagnostics intended to support therapy selection, biomarker discovery and biopharmaceutical drug development.
The company is also expanding its functional liquid biopsy platform through biopharmaceutical partnerships, co-development programs and strategic licensing opportunities.
